HK Stock MarketDetailed Quotes

02162 KEYMED BIO-B

Watchlist
  • 43.700
  • +0.150+0.34%
Not Open Nov 6 16:08 CST
12.22BMarket Cap-15017P/E (TTM)

About KEYMED BIO-B Company

Connoa Biomedical Technology Co., Ltd. is a biotechnology company with multiple clinical-stage assets, each of which is a strong competitor in its own competitive field. We focus on independently discovering and developing innovative biotherapeutics to meet a large number of unmet medical needs in the field of autoimmunity and oncology treatment. With a strong foundation in biomedical research, we have mastered in-house drug discovery and development techniques, including those that make up our innovative antibody discovery platform and our own novel T-cell redirection (NTcE) bispecific antibody platform. In less than five years since our establishment, we have consistently explored the extremely challenging field of disease treatment that is in short supply. We now have more than ten drug candidates in in-house development, five of which are in the clinical phase. Our own products, which are currently being developed, apply cutting-edge scientific findings and reflect our deep market insight. Driven by economic growth and health-care system reforms, health-care spending increased significantly in the first two decades of the new millennium. Due to rapid urbanization, changes in residents' lifestyles, and environmental changes, China's epidemiological focus is shifting from the prevalence of infectious diseases to the prevalence of cancer and other chronic diseases. These basic and evolving trends present new challenges to public health and reveal new areas of disease that place a heavy burden on society due to inadequate treatment options. To support our innovative biopharmaceutical research and development efforts, we have established a comprehensive integrated platform covering all key functions of biopharmaceutical development, including target validation, lead compound generation and optimization, preclinical evaluation, process development, translational research, clinical development and production. This integrated platform enables us to rapidly and cost-effectively discover, build, expand and advance our diverse pipeline of innovative and differentiated antibody therapies, including monoclonal antibodies, antibody-conjugated drugs, and bispecific antibodies.

Company Profile

Symbol02162
Company NameKEYMED BIO-B
ISINKYG5252B1023
Listing DateJul 8, 2021
Issue Price53.30
Shares Offered58.26M share(s)
FoundedApr 23, 2018
Registered AddressCayman Islands
ChairmanBo CHEN
Secretaryyanrongtanbairu zhang
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeFloor 4, Willow House, Cricket Square Grand Cayman KY1-9010 Cayman Islands
Head Office and Principal Place of BusinessRoom 1701, Tower 2, Lippo Centre, Queensway, Hong Kong
Fiscal Year Ends12-31
Employees1116
MarketHong Kong motherboard
Phone(028)88610620
Emailpr@keymedbio.com
Business Conoa Biomedical Technology Co., Ltd. is a biotechnology company focusing on the independent discovery and development of innovative biotherapeutics in the fields of autoimmunity and tumor treatment. The company also focuses on research and development of pharmaceutical products. The company's main products are CM310, CM326, CM313 and CM383, which can treat various types of type I immune diseases in adults, adolescents and children, such as moderate to severe atopic dermatitis, moderate to severe asthma, chronic rhinitis with nasal polyps, allergic rhinitis, and may also treat chronic obstructive pulmonary disease. The company has also built a fully integrated platform covering key functions for biopharmaceutical development. The company mainly operates in domestic and overseas markets in China.

Company Executives

  • Name
  • Position
  • Salary
  • Bo CHEN
  • Presidencies, CEO, Executive Director, Chairman of the Nomination Committee, Authorized Representative
  • --
  • Changyu Wang
  • Executive Director, Senior Vice President, Remuneration Committee Members, Authorized Representative
  • --
  • gang xu
  • Executive Director, Senior Vice President
  • --
  • qi chen
  • Non-executive Directors, Audit Committee Members
  • --
  • minchuan wang
  • Non-executive Directors
  • --
  • yilun liu
  • Non-executive Directors
  • --
  • xiaofan wang
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members
  • --
  • yang ke
  • Independent Non-Executive Director, Remuneration Committee Members, Audit Committee Members
  • --
  • zhuojian luo
  • Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
  • --
  • qian jia
  • Senior Vice President
  • --
  • yanrong zhang
  • Chief Financial Officer, Joint Company Secretary
  • --
  • bairu tan
  • Joint Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data